388 related articles for article (PubMed ID: 24837460)
1. Progress in central nervous system lymphomas.
Wang CC; Carnevale J; Rubenstein JL
Br J Haematol; 2014 Aug; 166(3):311-25. PubMed ID: 24837460
[TBL] [Abstract][Full Text] [Related]
2. New approaches in primary central nervous system lymphoma.
Fraser E; Gruenberg K; Rubenstein JL
Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718
[TBL] [Abstract][Full Text] [Related]
3. How I treat CNS lymphomas.
Rubenstein JL; Gupta NK; Mannis GN; Lamarre AK; Treseler P
Blood; 2013 Oct; 122(14):2318-30. PubMed ID: 23963042
[TBL] [Abstract][Full Text] [Related]
4. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
[TBL] [Abstract][Full Text] [Related]
6. Consolidation Therapy in Primary Central Nervous System Lymphoma.
Kim P; Omuro A
Curr Treat Options Oncol; 2020 Jul; 21(9):74. PubMed ID: 32725379
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
8. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis and management of primary CNS lymphoma.
Roth P; Korfel A; Martus P; Weller M
Expert Rev Anticancer Ther; 2012 May; 12(5):623-33. PubMed ID: 22594897
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma: A curable disease.
Batchelor TT
Hematol Oncol; 2019 Jun; 37 Suppl 1():15-18. PubMed ID: 31187523
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Lymphoma: Novel Therapies.
Fortin Ensign SP; Gathers D; Wiedmeier JE; Mrugala MM
Curr Treat Options Oncol; 2022 Jan; 23(1):117-136. PubMed ID: 35182298
[TBL] [Abstract][Full Text] [Related]
13. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of primary CNS lymphoma.
Korfel A; Schlegel U
Nat Rev Neurol; 2013 Jun; 9(6):317-27. PubMed ID: 23670107
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
Rubenstein JL; Hsi ED; Johnson JL; Jung SH; Nakashima MO; Grant B; Cheson BD; Kaplan LD
J Clin Oncol; 2013 Sep; 31(25):3061-8. PubMed ID: 23569323
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
18. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
[TBL] [Abstract][Full Text] [Related]
19. Evolving Treatments for Primary Central Nervous System Lymphoma.
Ferreri AJM; Holdhoff M; Nayak L; Rubenstein JL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():454-466. PubMed ID: 31099614
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
Sanders S; Chua N; Larouche JF; Owen C; Shafey M; Stewart DA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1505-1510. PubMed ID: 30965138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]